2nd editionUnmet challenges in high risk hematological malignancies: from benchside to clinical practiceTurin, September 13-14, 2021 Starhotels Majestic

Scientific board: Marco Ladetto (Alessandria)Umberto Vitolo (Candiolo-TO)

1

AUSPICES FACULTY

UNIVERSITÀ DEL PIEMONTE ORIENTALE

ISTITUTO DI CANDIOLO - FONDAZIONE DEL PIEMONTE PER L’ONCOLOGIA - IRCCS

AZIENDA OSPEDALIERA DI ALESSANDRIA SANTI ANTONIO E BIAGIO E CESARE ARRIGO

UNIVERSITÀ DI TORINO

AZIENDA OSPEDALIERO-UNIVERSITARIACittà della Salute e della Scienza di Torino - Presidio Ospedaliero Le Molinette

FIL - Fondazione Italiana Linfomi

GITMO - Gruppo Italiano per il Trapianto di Midollo Osseo, cellule staminali emopoietiche e terapia cellulare

SIE - Società Italiana di Ematologia

SIES - Società Italiana di Ematologia Sperimentale

RETE ONCOLOGICA DEL PIEMONTE E DELLA VALLE D’AOSTA

Emanuele AngelucciStephen M. AnsellHervé Avet LoiseauMonica BalzarottiRenato BassanMario BoccadoroAlan K. BurnettAngelo Michele CarellaAnnalisa ChiappellaDaniela CilloniAntonio CuneoBrunangelo FaliniSimone FerreroRobin FoàNathan H. Fowler Gianluca GaidanoPaolo GhiaJohn GribbenPaola GuglielmelliOlivier HermineWolfgang HiddemannPeter HillmenMartin Hutchings Nicolaus Kroeger Marco Ladetto

Genoa, ItalyRochester, USAToulouse, FranceRozzano (MI), ItalyMestre (VE), ItalyTurin, ItalyGlasgow, UKGenoa, ItalyMilan, ItalyTurin, ItalyFerrara, ItalyPerugia, ItalyTurin, ItalyRome, ItalyHouston, USA Novara, ItalyMilan, ItalyLondon, UKFlorence, ItalyParis, FranceMunich, GermanyLeeds, UKCopenhagen, DenmarkHamburg, GermanyAlessandria, Italy

Alessandra LaroccaMaurizio MartelliMassimo MassaiaGrzegorz S. NowakowskiOwen A. O’Connor Fabrizio PaneStefano A. PileriChristiane PottPatrizia PregnoAlessandro RambaldiLuigi RigacciGiuseppe SaglioValeria SantiniStephen J. SchusterMichele SpinaEnrico TiacciJan Trka Adriano VendittiCarlo ViscoUmberto VitoloElena ZamagniEmanuele Zucca

Turin, ItalyRome, ItalyCuneo, ItalyRochester, USACharlottesville, USA Naples, ItalyMilan, ItalyKiel, GermanyTurin, ItalyBergamo, ItalyRome, ItalyTurin, ItalyFlorence, ItalyPhiladelphia, USAAviano (PN), ItalyPerugia, ItalyPrague, Czech RepublicRome, ItalyVerona, ItalyCandiolo (TO), ItalyBologna, ItalyBellinzona, Switzerland

Unmet challenges in high risk hematological malignancies:

from benchside to clinical practice

MONDAY SEPTEMBER 13, 2021

2 3

09.00 Welcome and introduction M. Ladetto, U. Vitolo and Scientific Authorities

09.30-11.00 Hodgkin Lymphoma and T-cell Lymphoma Chairmen: M. Spina, U. Vitolo

09.30 Genetics and biology of classical Hodgkin Lymphoma: clinical implications E. Tiacci

09.50 How I treat high risk Hodgkin Lymphoma S.M. Ansell

10.10 Histopathology and molecular biology of T-cell Lymphoma S.A. Pileri

10.30 How I treat high risk T-cell Lymphomas O.A. O’Connor

10.50 Panel Discussion

11.00-11.30 LECTURE I Chairman: M. Ladetto

Optimizing outcomes for CD19-directed CAR-T cell therapy in refractory B-cell lymphomas S.J. Schuster

11.30-12.45 Mantle Cell Lymphoma Chairmen: M. Ladetto, M. Martelli 11.30 Biological identification of high risk Mantle Cell Lymphoma C. Pott

11.50 How I treat high risk Mantle Cell Lymphoma in first line O. Hermine

12.10 How I treat relapsed/refractory Mantle Cell Lymphoma C. Visco

12.30 Panel Discussion

12.45-14.00 Lunch

4 5

MONDAY SEPTEMBER 13, 2021 Unmet challenges in high risk hematological malignancies:

from benchside to clinical practice16.00-17.10 Follicular Lymphoma Chairmen: M.Ladetto, L. Rigacci

16.00 Biology of high risk Follicular Lymphoma S. Ferrero

16.20 How I treat high risk Follicular Lymphoma in first line W. Hiddemann

16.40 How I treat relapsed/refractory Follicular Lymphoma N.H. Fowler

17.00 Panel Discussion

17.10-18.20 Chronic Lymphocytic Leukemia Chairmen: A. Cuneo, P. Ghia

17.10 Biology of high risk Chronic Lymphocytic Leukemia M. Massaia

17.30 Defining high risk Chronic Lymphocytic Leukemia in 2021 from the clinician’s perspective J. Gribben

17.50 How I treat relapsed/refractory Chronic Lymphocytic Leukemia P. Hillmen

18.10 Panel Discussion

14.00-14.30 LECTURE II Chairman: U. Vitolo

Impact of Lugano conferences in the lymphoma research E. Zucca

14.30-16.00 Diffuse large B-Cell Lymphoma Chairmen: M. Balzarotti, U. Vitolo 14.30 Biological identification of high risk DLBCL G. Gaidano

14.50 How I treat high risk DLBCL in first line A. Chiappella

15.10 How I treat DLBCL in relapse G.S. Nowakowski

15.30 Novel antibodies in aggressive lymphomas M. Hutchings

15.50 Panel Discussion

6

9.15-10.25 Multiple Myeloma Chairmen: M. Boccadoro, M. Massaia

09.15 Biology of high risk Multiple Myeloma H. Avet-Loiseau

09.35 How I treat young high risk Multiple Myeloma E. Zamagni

09.55 How I treat elderly high risk Multiple Myeloma A. Larocca

10.15 Panel Discussion

10.30-11.00 LECTURE III Chairman: G. Saglio

Beyond 3+7 in Acute Myelogenous Leukemia A.K. Burnett

TUESDAY SEPTEMBER 14, 2021

7

11.00-12.10 Myeloproliferative Disorders Chairmen: A.M. Carella, G. Saglio

11.00 Biology of high risk myeloproliferative disorders P. Guglielmelli

11.20 How I treat high risk Chronic Myeloid Leukemia P. Pregno

11.40 How I treat high risk myeloproliferative neoplasms D. Cilloni

12.00 Panel Discussion

12.10-13.10 Lunch

Unmet challenges in high risk hematological malignancies:

from benchside to clinical practice

TUESDAY SEPTEMBER 14, 2021

13.10-14.20 Acute Lymphoblastic Leukemia and Transplantation Chairmen: R. Foà, A. Rambaldi

13.10 Biology of High Risk Acute Lymphoblastic Leukemia J. Trka

13.30 How I treat high risk Acute Lymphoblastic Leukemia in first line R. Bassan

13.50 Allogeneic transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes N. Kroeger

14.10 Panel Discussion

8 9

Unmet challenges in high risk hematological malignancies:

from benchside to clinical practice

14.20-15.30 Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Chairmen: E. Angelucci, F. Pane

14.20 Genomic identification of high risk Acute Myeloid Leukemia B. Falini

14.40 How I treat high risk Myelodysplastic Syndromes V. Santini

15.00 How I treat elderly Acute Myeloid Leukemia patients A. Venditti

15.20 Panel Discussion

15.30-15.45 Closing remarks M. Ladetto, U. Vitolo

stru

chel

.com

MEETING VENUE Starhotels Majestic Corso Vittorio Emanuele II, 5410123 Torino, Italy Tel. +39 011 539153

ITALIAN CME CREDITSAn Italian CME application has been submitted as follows: • Provider Studio ER Congressi SRL: ID 828- 282393. • No. 9,1 CME credits for Physicians (Haematology, Oncology, Internal Medicine) and Biologists.• Educational objective: “linee guida-protocolli-procedure”.

OFFICIAL LANGUAGEEnglish

BADGE AND CERTIFICATE OF ATTENDANCEAll registered participants and speakers will be given a badge which must be worn in order to be admitted to the scientific sessions.A certificate will be given to all participants at the end of the meeting.

SCIENTIFIC BOARD Marco Ladetto MD Associate Professor in HaematologyUniversity of Eastern Piedmont Amedeo AvogadroS.S. Antonio and Biagio and Cesaro Arrigo HospitalVia Venezia, 16 - 15121 Alessandria, Italy

Umberto Vitolo MD Hematology Consultant Candiolo Cancer Institute - FPO-IRCCSStrada Provinciale, 142 - 10060 Candiolo (TO), Italy

SCIENTIFIC COMMITTEEProf. Mario Boccadoro (Turin)Prof. Gianluca Gaidano (Novara)Prof. Massimo Massaia (Cuneo)

Prof. Giuseppe Saglio (Orbassano - TO)

ORGANIZING SECRETARIAT Studio E.R. Congressi Via De’ Poeti, 1/7 - 40124 Bologna, ItalyPhone +39 051 4210559 - Fax +39 051 4210174E-mail: ercongressi@ercongressi.itwww.ercongressi.it

GENERAL INFORMATION

The organization is proud to compensate itsgreenhouse gas emissions investing in thecarbon offset project: “Mytrah Wind Power”.

With an unrestricted educational grant of: